0.45
-0.0716(-13.85%)
Currency In USD
| Previous Close | 0.52 |
| Open | 0.51 |
| Day High | 0.51 |
| Day Low | 0.43 |
| 52-Week High | 102 |
| 52-Week Low | 0.43 |
| Volume | 2.55M |
| Average Volume | 1.92M |
| Market Cap | 3.44M |
| PE | -0.01 |
| EPS | -34.56 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 6.44 |
| Change | -0.07 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.45 as of June 01, 2025 at a share price of $0.445. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.44 as of June 01, 2025 at a share price of $0.445.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
GlobeNewswire Inc.
May 30, 2025 12:15 PM GMT
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif., May 30, 202
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
GlobeNewswire Inc.
May 08, 2025 12:15 PM GMT
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics th
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
GlobeNewswire Inc.
Apr 30, 2025 12:15 PM GMT
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics